Subfertility
Conditions
Brief summary
Treatment-related quality of life and patient satisfaction retrieved from the second questionnaire (Q2), which is completed at the end of each stimulation cycle; after the agonist trigger and before the oocyte retrieval.
Detailed description
Patient feedback derived from the third questionnaire (Q3), which is completed within 3 weeks after completing the second stimulation cycle.
Interventions
DRUG1 mg/1 ml
DRUGoplossing voor injectie
DRUG1 mg/ml
DRUGInjektionslösung
DRUGsolution injectable
DRUGCerazette 75 microgram film-coated tablets
Sponsors
Universitair Ziekenhuis Gent
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment-related quality of life and patient satisfaction retrieved from the second questionnaire (Q2), which is completed at the end of each stimulation cycle; after the agonist trigger and before the oocyte retrieval. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient feedback derived from the third questionnaire (Q3), which is completed within 3 weeks after completing the second stimulation cycle. | — |
Countries
Belgium
Outcome results
None listed